Learn More
We have mitigated acoustic noise in a 1.5 T cylindrical MRI scanner equipped with epoxy-potted, shielded gradients. It has been widely assumed that MRI acoustic noise comes overwhelmingly from vibrations of the gradient assembly. However, with vibration-isolated gradients contained in an airtight enclosure, we found the primary sources of acoustic noise to(More)
Friction-induced moments and subsequent cup loosening can be the reason for total hip joint replacement failure. The aim of this study was to measure the in vivo contact forces and friction moments during walking. Instrumented hip implants with Al2O3 ceramic head and an XPE inlay were used. In vivo measurements were taken 3 months post operatively in 8(More)
To investigate the pharmacokinetics and the disposition of levoprotiline after i.v. and p.o. administration and to assess the absolute bioavailability, 12 healthy volunteers (11 women, 1 man) were given a 10 min i.v. infusion of 15 mg and a p.o. dose of 75 mg in a two-way crossover study. Blood and urine samples were collected after each dose. Unchanged(More)
1. The disposition of [14C]-labelled benazepril HCl, an ACE-inhibitor, was studied in four normal adult volunteers after a single oral dose of 20 mg and after repeated doses of 20 mg once daily for 5 days. Radioactivity was measured in plasma, urine and faeces. The prodrug ester benazepril and the pharmacologically active metabolite benazeprilat were(More)
Introduction Acoustic noise in MRI scanners has long been a concern for patient comfort and, on occasion, for patient safety [1,2]. Acoustic noise interferes with communication between MRI physicians and operators. Acoustic noise also provides an unwanted stimulus and interference during fMRI studies. We have studied acoustic noise in a 1.5 T cylindrical(More)
To investigate the pharmacokinetics of benazepril hydrochloride in special populations, single or multiple doses between 5 and 20 mg of the new drug were given, and the pharmacokinetics of unchanged benazepril and its pharmacologically active metabolite benazeprilat were compared with those in healthy male volunteers. In elderly subjects and patients with(More)
A specific and sensitive gas chromatographic-mass spectrometric method for the simultaneous quantification of unchanged 3-[( 1-ethoxycarbonyl-3-phenyl-(1S)-propyl]amino)-2,3,4,5-tetrahydro-2-oxo-1- 1-(3S)-benzazepine-1-acetic acid (I) and its active metabolite, the dicarboxylic acid (II), in plasma and urine has been developed and validated. 2H5-labelled(More)
The pharmacokinetics and pharmacodynamics of a single oral dose benazepril.HCl 10 mg have been studied in 15 healthy volunteers aged 65 to 80 y. The kinetics of unchanged benazepril and its active metabolite benazeprilat did not differ significantly in males and females, so the combined kinetic data from all 15 elderly subjects were compared with a(More)
A specific and sensitive gas chromatographic/mass spectrometric method was developed and validated for the quantitative determination of the aromatase inhibitor CGS 16 949 in plasma and urine. A deuterium-labelled analogue of CGS 16 949 was used as internal standard. The analysis of spiked samples demonstrated the good accuracy and precision of the method.(More)